Effective adoptive immunotherapy of triple-negative breast cancer by folate receptor-alpha redirected CAR T cells is influenced by surface antigen expression level

Journal of Hematology and Oncology

Volumn 9, Issue 1, 2016, Pages

  Song, De Gang ^a,d   Ye, Qunrui ^a   Poussin, Mathilde ^a   Chacon, Jessica A ^a   Figini, Mariangela ^b   Powell, Daniel J ^a,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d INTREXON CORPORATION   (United States)

Author keywords

Chimeric antigen receptor; Folate receptor alpha; Immunotherapy; Triple negative breast cancer

Indexed keywords

CD27 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; FOLATE RECEPTOR 1; MEMBRANE ANTIGEN; FOLR1 PROTEIN, HUMAN; LYMPHOCYTE ANTIGEN RECEPTOR;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER CELL LINE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; LYMPHOCYTE TRANSFER; MDA MB 231 CELL LINE; MOUSE; NONHUMAN; OVARY TUMOR; PROTEIN EXPRESSION; T LYMPHOCYTE; TRIPLE NEGATIVE BREAST CANCER; TUMOR XENOGRAFT; ANIMAL; CELL CULTURE; CHEMISTRY; GENETICS; IMMUNOLOGY; PROCEDURES; STANDARDS; TRANSPLANTATION; XENOGRAFT;

ANIMALS; CELLS, CULTURED; FEMALE; FOLATE RECEPTOR 1; HETEROGRAFTS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MICE; OVARIAN NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84979225446     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/s13045-016-0285-y     Document Type: Article

References (35)

1. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363(20):1938-48.
2. Tan DS, et al. Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat. 2008;111(1):27-44.
3. Cleator S, Heller W, Coombes RC. Triple-negative breast cancer: therapeutic options. Lancet Oncol. 2007;8(3):235-44.
4. O'Shannessy DJ, et al. Folate receptor alpha (FRA) expression in breast cancer: identification of a new molecular subtype and association with triple negative disease. Springerplus. 2012;1(1):1-9.
5. Rochman H, Selhub J, Karrison T. Folate binding protein and the estrogen receptor in breast cancer. Cancer Detect Prev. 1985;8(1-2):71.
6. Kelley KM, Rowan BG, Ratnam M. Modulation of the folate receptor α gene by the estrogen receptor mechanism and implications in tumor targeting. Cancer Res. 2003;63(11):2820-8.
7. Xia W, Low PS. Folate-targeted therapies for cancer. J Med Chem. 2010;53(19):6811-24.
8. Clifton GT, et al. Folate receptor α: a storied past and promising future in immunotherapy. Human Vaccines. 2011;7(2):183-90.
9. Song D-G, et al. CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo. Blood. 2012;119(3):696-706.
10. Song D-G, et al. In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB). Cancer Res. 2011;71(13):4617-27.
11. Milone MC, et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther. 2009;17(8):1453-64.
12. Parry RV, et al. CD28 and inducible costimulatory protein Src homology 2 binding domains show distinct regulation of phosphatidylinositol 3-kinase, Bcl-xL, and IL-2 expression in primary human CD4 T lymphocytes. J Immunol. 2003;171(1):166-74.
13. Figini M, et al. Conversion of murine antibodies to human antibodies and their optimization for ovarian cancer therapy targeted to the folate receptor. Cancer Immunol Immunother. 2009;58(4):531-46.
14. Wolfl M, et al. Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities. Blood. 2007;110(1):201-10.
15. Siu MK, et al. Paradoxical impact of two folate receptors, FRα and RFC, in ovarian cancer: effect on cell proliferation, invasion and clinical outcome. PLoS One. 2012;7(11):e47201.
16. Necela BM, et al. Folate receptor-α (FOLR1) expression and function in triple negative tumors. PLoS One. 2015;10(3):e0122209.
17. Hartmann LC, et al. Folate receptor overexpression is associated with poor outcome in breast cancer. Int J Cancer. 2007;121(5):938-42.
18. Zhang Z. et al. Folate receptor α associated With triple-negative breast cancer and poor prognosis. Arch Pathol Lab Med. 2013.
19. Knutson KL, et al. T-cell immunity to the folate receptor alpha is prevalent in women with breast or ovarian cancer. J Clin Oncol. 2006;24(26):4254-61.
20. Konner JA, et al. Farletuzumab, a humanized monoclonal antibody against folate receptor α, in epithelial ovarian cancer: a phase I study. Clin Cancer Res. 2010;16(21):5288-95.
21. Thomas A, Maltzman J, Hassan R. Farletuzumab in lung cancer. Lung Cancer. 2013;80(1):15-8.
22. Maude SL, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507-17.
23. Tran T, et al. Enhancement of folate receptor α expression in tumor cells through the glucocorticoid receptor: a promising means to improved tumor detection and targeting. Cancer Res. 2005;65(10):4431-41.
24. Tchou J, et al. Mesothelin, a novel immunotherapy target for triple negative breast cancer. Breast Cancer Res Treat. 2012;133(2):799-804.
25. Lanitis E, et al. Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor. Mol Ther. 2012;20(3):633-43.
26. Riker A, et al. Immune selection after antigen-specific immunotherapy of melanoma. Surgery. 1999;126(2):112-20.
27. Grupp SA, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509-18.
28. Lanitis E, et al. Chimeric antigen receptor T cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo. Cancer Immunol Res. 2013;1(1):43-53.
29. Anurathapan U et al. Kinetics of tumor destruction by chimeric antigen receptor-modified T cells. Mol Ther. 2013.
30. Edelman MJ, et al. Multicenter trial of EC145 in advanced, folate-receptor positive adenocarcinoma of the lung. J Thorac Oncol. 2012;7(10):1618-21.
31. Wu J, et al. Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia. J Hematol Oncol. 2015;8(1):1.
32. Fan G, et al. Bispecific antibodies and their applications. J Hematol Oncol. 2015;8(1):1.
33. Stone JD, et al. A sensitivity scale for targeting T cells with chimeric antigen receptors (CARs) and bispecific T-cell engagers (BiTEs). Oncoimmunology. 2012;1(6):863-73.
34. Rodgers DT, et al. Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies. Proc Natl Acad Sci. 2016;113(4):E459-68.
35. Wu CY, et al. Remote control of therapeutic T cells through a small molecule-gated chimeric receptor. Science. 2015;350(6258):aab4077.